Loss of MSH6 expression was associated with a better median OS time in the group of high-grade astrocytoma patients only treated with radiotherapy (HR=2.17, 95% C.I. 1.14-4.11, P=0.015) (Figure 2B); meanwhile no significant differences were found in the group of patients treated with radiotherapy plus chemotherapy (HR=1.21, 95% C.I. 0.64-2.26, P=0.558) (Figure 2C). The gene discussed is MSH6; the disease is astrocytoma (excluding glioblastoma).